BTIG analyst Marie Thibault has maintained a Buy rating on Boston Scientific Corporation (NYSE: BSX) while lowering the price target from $65 to $60. This adjustment signals a slight recalibration of near-term valuation expectations for the medical device manufacturer, though the firm continues to view the stock as an attractive investment opportunity relative to its peers.

The price target reduction reflects BTIG’s ongoing assessment of Boston Scientific’s growth trajectory and market positioning. While the firm retains its positive outlook, the lowered ceiling suggests a more conservative estimate of achievable share price appreciation in the current market environment. Investors should note that the Buy rating indicates continued confidence in the company’s long-term fundamentals despite the modest downward revision in the target price.

Boston Scientific remains a key player in the interventional solutions and medical device sector. The firm’s decision to keep the Buy rating intact implies that the core investment thesis—likely driven by product innovation, market share gains, or strong pipeline execution—remains valid. However, the $5 reduction in the price target may account for broader sector headwinds or specific operational factors that have tempered immediate upside potential.

Analyst Action Details

This move by BTIG is part of the regular cycle of equity research updates that institutional investors monitor closely. While the rating remains unchanged, the adjustment in the price target provides a nuanced view of the stock’s near-term performance expectations. Market participants will likely watch for further commentary from Marie Thibault regarding specific drivers behind this valuation shift in subsequent reports.

What the Numbers Show

The maintenance of the Buy rating alongside a lower price target suggests that while BTIG sees sustained value in Boston Scientific, the margin for error in execution or the timeline for value realization may have shifted slightly. The $60 target represents a specific valuation anchor that investors can use to gauge entry and exit points, balancing the firm’s long-term optimism with short-term realism.

Boston Scientific Corporation reported second-quarter revenues of $5.442 billion on Wednesday, surpassing the consensus estimate of $5.361 billion and its own guidance range of $5.34 billion to $5.44 billion. Despite the quarterly beat, the medical technology giant lowered its fiscal 2026 outlook, citing unexpected slowdowns in the U.S. market for its Watchman heart implant and intensified competitive share movement in the electrophysiology (EP) sector. The revised guidance signals near-term pressure on growth, with adjusted earnings per share (EPS) guidance reduced from $3.34-$3.41 to $3.28-$3.32, below the consensus of $3.36.

The company’s adjusted earnings for the quarter came in at 86 cents per share, exceeding both the consensus of 83 cents and management’s guidance of 82-84 cents. Mike Mahoney, chairman and CEO of Boston Scientific, stated that the team delivered a solid quarter while navigating a dynamic environment, emphasizing disciplined execution and prioritizing investments in high-impact opportunities. However, the firm acknowledged that compounding clinical evidence has impacted referral patterns for Watchman, while competitive dynamics in EP were more severe than anticipated.

Fiscal 2026 Guidance Reduction

Boston Scientific cut its full-year 2026 sales guidance from $21.479 billion-$21.78 billion to $21.178 billion-$21.379 billion, missing the consensus estimate of $21.562 billion. The company expects these market dynamics to persist into 2027, resulting in revenue growth below its weighted average management guidance (WAMGR) and limited adjusted EPS growth. Management projects meaningful improvement in revenue and EPS growth profiles only by 2028.

For the third quarter of 2026, Boston Scientific forecasts net sales growth of approximately 3%-5% on both reported and organic bases, equivalent to sales of $5.217 billion-$5.318 billion. This range falls short of the consensus estimate of $5.358 billion. Adjusted earnings for Q3 are expected to be 80-82 cents per share, versus the consensus of 83 cents.

Restructuring Plan and Cost Savings

To address controllable headwinds, Boston Scientific initiated a restructuring plan earlier this week. According to an SEC filing, the plan will generate total pre-tax charges of $700 million to $800 million, including future cash outlays of $600 million to $700 million. Once fully implemented, the restructuring is expected to reduce gross annual pre-tax expenses by about $500 million. A significant portion of these savings will be earmarked for strategic growth investments.

What the Numbers Show

The divergence between strong Q2 operational performance and weakened forward guidance highlights structural challenges in key product categories. While the company managed to beat quarterly estimates through disciplined execution, the specific headwinds in Watchman and EP markets suggest broader industry shifts rather than isolated execution errors. The decision to incur $700 million-$800 million in pre-tax charges for restructuring indicates a strategic pivot to protect long-term margins, albeit at the cost of near-term earnings visibility. Investors should note that the company explicitly expects revenue growth to remain below consensus levels through 2027, with recovery anticipated only in 2028.

Boston Scientific shares declined 6.17% to $43.22 at the time of publication, reflecting investor concern over the lowered outlook despite the quarterly beat.